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Background: The purpose of this study was to describe the natural history of severe congenital neutropenia (SCN)
in 14 patients with G6PC3 mutations and enrolled in the French SCN registry.
Methods: Among 605 patients included in the French SCN registry, we identified 8 pedigrees that included 14
patients with autosomal recessive G6PC3 mutations.
Results: Median age at the last visit was 22.4 years. All patients had developed various comordibities, including
prominent veins (n = 12), cardiac malformations (n = 12), intellectual disability (n = 7), and myopathic syndrome with
recurrent painful cramps (n = 1). Three patients developed Crohn ? s disease, and five had chronic diarrhea with
steatorrhea. Neutropenia was profound (<0.5 ? 10 9/l) in almost all cases at diagnosis and could marginally fluctuate.
The bone marrow smears exhibited mild late-stage granulopoeitic defects. One patient developed myelodysplasia
followed by acute myelogenous leukemia with translocation (18, 21) at age 14 years, cured by chemotherapy
and hematopoietic stem cell transplantation. Four deaths occurred, including one from sepsis at age 5, one from
pulmonary late-stage insufficiency at age 19, and two from sudden death, both at age 30 years. A new homozygous
mutation (c.249G > A /p.Trp83*) was detected in one pedigree.
Conclusions: Severe congenital neutropenia with autosomal recessive G6PC3 mutations is associated with
considerable clinical heterogeneity. This series includes the first described case of malignancy in this neutropenia.Introduction
Severe congenital neutropenia (SCN) encompasses a group
of rare diseases associated with neutropenia and other
developmental defects. To date in 2014, a total of 18 genes
have been identified as responsible for this entity [1]. In
2009, Botzug et al. [2] described a subgroup of SCN
patients with biallelic G6PC3 mutations, encoding the
catalytic subunit 3 of glucose-6-phosphatase. In addition
to severe neutropenia, this group of patients exhibits three
major features: skin abnormalities with a visible perive-
nous system, cardiac abnormalities (mainly atrial septal* Correspondence: jean.donadieu@trs.aphp.fr
3AP-HP, Registre fran?ais des neutrop?nies chroniques s?v?res, Centre de
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unless otherwise stated.defect), and urogenital abnormalities. By 2014, this entity,
also termed SCN 4 or Dursun syndrome, had been
reported in 61 cases [3-7]. Based on enrollment in the
French SCN registry, we identified 14 cases from eight
pedigrees, including two pedigrees previously reported
prior to gene identification. Indeed, in 1994, Stoll et al. [8]
described a new syndrome associating facial dysmorphia,
skin disorder, cardiac and/or urogenital abnormalities,
recurrent infections, and neutropenia. Previously, in 1982,
Vannier et al. reported a case associating Crohn? s disease
and neutropenia [9], the first such case reported. This
series describes the long-term outcome of such patients
and describes several adverse consequences such as
leukemia and death and also one pregnancy, expanding
the phenotypic picture of this disease.tral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Organization of the French registry and data monitoring
All patients included in this study were registered in the
French Severe Chronic Neutropenia Registry, created in
1993 and based on prospective enrollment. We included
all types of congenital neutropenia [1]. The registry re-
ceived national certification in 2008 by the French health
authorities, and 35 French regional pediatric hematology?
oncology clinical units participate in it. Data monitoring
was based on a review of medical records collected by a
clinical research associate who visited each center yearly.
The patient or a legal guardian provided written informed
consent before being included in the registry. Several
reports of the registry are available elsewhere [10,11]. In
addition to information about the hematological outcome,
we collect information on patient morphological features.
G6PC3 mutations were suspected if a patient presented
with a congenital neutropenia associated with at least one
additional non-hematologic aberration, such as increased
superficial venous markings, congenital heart disease,
or urogenital anomalies. Patient UPN5248 has already
been described as patient #9 in the initial description
[2]; patients UPN5192, UPN5193, and UPN5194 were
described in 1994 [8]; and patient #4 was included in a
survey about hematopoietic stem cell transplantation in
congenital neutropenia [12]. Finally, patient UPN5273 was
patient #1 in the first report describing this syndrome
worldwide in 1982 [9].
Clinical investigation
Demographic, auxologic, nutritional, and hematological
information was collected, as were results of liver tests
and immunological tests, and infectious history. Septi-
cemia, cellulitis, bacterial or fungal pneumonia, osteitis,
pyelonephritis, and liver abscess were considered as severe
infections and systematically recorded, as were causative
germs. Minor infections were those for which patients did
not seek medical surveillance such as stomatological or
ear, nose, and throat infections. These events were often
omitted in the medical records. Immunoglobulin (Ig)
levels were analyzed according to age. Age at diagnosis
was defined by the age at the first pathological manifest-
ation leading to the diagnosis of chronic neutropenia.
Definition of hematological features and hematological
complications
The initial complete blood count (CBC) value was the
median value of the three first CBCs collected in each
patient? s lifetime. Baseline CBC was considered if samples
were collected during routine consultations, with the ex-
ception of periods involving granulocyte colony-stimulating
factor (G-CSF) therapy and any hematological complica-
tions as defined below. The World Health Organization
2008 classification was used to define acute leukemia.Myeloid blockage was defined according to a previous
study [13].
Clinical phenotype
We routinely analyzed parameters such as auxologic and
major medical events requiring medical management.
We collected clinical information on facial features, skin
aspect, heart and urogenital anomalies, and any other
malformations.
G6PC3 gene sequencing
The patients or their parents gave written informed consent
for genetic testing. Genomic DNA was extracted from
blood with standard procedures. The coding sequence and
exon? intron boundaries of the G6PC3 gene were amplified
using primers and PCR conditions described previously [2].
Purified PCR products were sequenced in both directions
using the BigDye Terminator chemistry (Life Technologies,
Saint-Aubin, France) on an ABI3730 Genetic Analyser.
Sequences were analyzed with the Seqscape software v2.2.
We numbered mutations as recommended by the Human
Genome Variation Society (http://www.hgvs.org/), using the
reference sequence NM_003467.2. Among the 605 patients
with SCN included in the registry, G6PC3 mutations were
screened in 85 unrelated patients. G6PC3 was screened
if neutropenia was associated with comorbidities like a
congenital heart defect or prominent veins and if ELANE
and SBDS mutations had been previously excluded.
Statistical analysis
Stata software version 10 was used for all statistical
analyses. Lower and upper interquartile (p25 and p75,
respectively) and median values were used to depict the
distribution of quantitative variables. For survival analysis,
the endpoint was death. The period taken into account
was the time interval from birth to the first date when the
event was observed or to the last examination when no
event occurred. The Kaplan? Meier method was used to
estimate survival rates, with a cut-off date of April 1, 2014.
Literature review
To identify all publications related to G6PC3-associated
neutropenia to summarize reported cases, we first screened
PubMed, with the key words ?G6PC3 and neutropenia or
Dursun syndrome ? . We then checked the bibliography
of each article to identify additional references and
avoid duplicates.
Results
Demographic data
Fourteen patients including eight males, originating from
eight families, were identified among 605 patients (2.1%)
included in the French SCN registry. The median age at
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total follow-up period was 308 patient years.
Genetics
We analyzed eight families, six originated from France
and two from North Africa (Algeria). Pedigree study dem-
onstrated common ancestors in two families (Figure 1A,
F) where cases were found in apparently separated
branches. We identified a homozygous G6PC3 mutation
in seven families. Four of them were truncating mutations
(W83* (family A), R161* (D), and R189* in pedigrees G
and H), and two were missense mutations (R253H and
G260R in families B, E, and F). We identified a compoundFigure 1 Genealogic tree of the eight described families. Filled-in circle
pedigree are designed by a letter (A to H).heterozygote genotype ([c.[829C > T];[677 + 1G >A], p.
[Q277*]; [?]) in pedigree C (Figure 1, Table 1). This pro-
band (pedigree C, Table 1) has been previously described
(#9) [2]. All identified G6PC3 mutations also have been
previously described except the nonsense mutation W83*
in exon 2.
Features at birth and clinical presentation
The median age at first manifestation was 0.02 years.
Initial diagnoses were very heterogeneous ? Kabuki syn-
drome in one case, Pierre Robin sequence suspected in
one but not confirmed, Shwachman-Diamond syndrome
in three, and Fanconi anemia in two ? while in the others or squares represent affected cases with G6PC3 neutropenia. Each
Table 1 Summary of the clinical and biological features of the 14 patients
Pedigree UPN Sex/age/
vital status
G6PC3 genotype Age at diagnostic Median ANC/AMC Others hematological abnormalities Therapy
A 5194 F/36/L c.[249G > A];[249G > A]
p.[W83*];[W83*]
New born ANC: 0.7 Mild Thrombocytopenia/Mild
anemia prior leukemia/AML
at age of 14 y
HSCT
AMC: 0.28
5193 M/17/D New Born ANC 0.383 G-CSF
AMC: 1.44
5192 F/29/L New Born ANC 0.411 Mild Anemia Mild Thrombocytopenia G-CSF
AMC 1.11
5131 M/30/D New Born ANC: 1.368 AMC 0.55 Mild Anemia No
5130 M/24/L New born ANC 0.314 Mild Anemia G-CSF
AMC 0.92
B 6262 M/13/L c.[758G > A];[758G > A]; 7 months ANC 0.54 Mild anemia G-CSF
p.[R253H];[R253H] AMC 0.56
C 5248 F/19/L c.[829C > T];[677 +1G > A] New born ANC 0.3 No G-CSF
p.[Q277*]; [?] AMC 1.276
D 5643 M/17/L c.[481C > T];[481C > T] New born ANC 0.405 Mild Anemia G-CSF
p.[R161*];[R161*] AMC 0.31 Mild Thrombocytopenia LD steroid
E 6536 M/16/L c.[778G > C];[778G > C] New born ANC 1.071 No
p.[G260R];[G260R] AMC: 0.41
6420 F/3/L New born ANC 0.4 No
AMC 0.756
F 5273 F/50 L c.[778G > C];[778G > C] 7 months ANC 0.7 Severe Anemia G-CSF
p.[G260R];[G260R] AMC 0.5 LD steroid
G 5340 F/29/L c.[565C > T];[565C > T] New born ANC 0.52 No G-CSF
p.[R189*];[R189*] AMC 0.34
5847 M/30/D 4.5 years ANC 0.565 Severe Thrombocytopenia No
AMC 0.16 Mild Anemia
H 5805 M/5 D c.[565C > T];[565C > T] New born ANC 1.03 Mild Anemia GCSF
p.[R189*]; [R189*] AMC 0.69 Mild Thrombopenia
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Table 1 Summary of the clinical and biological features of the 14 patients
Pedigree Severe infections Cardiac abnormalities Urogenital
abnormalities
Cutaneous
abnormalities
Digestive tract Other findings Neurodev. difficulties
A Yes Aortic insufficiency Grade III RVU Prominent veins,
cutis laxa
Steatorrhea Heart failure Yes
urethral duplication Frontal bossing, thick lips,
prognathism Respiratory
failure Hypothyroidism
Yes Repeated pneumonitis
with bronchiectasis and lethal
respiratory insufficiency
ASD/surgery Bilateral
cryptorchidism
Prominent veins,
cutis laxa
Steatorrhea Frontal bossing, thick lips,
prognathism
Yes
Hypospadias
Yes ASD/surgery Bilateral grade I RVU Prominent veins,
cutis laxa
Steatorrhea Respiratory failure Yes
thick lips, prognathism
No PDA Overriding aorta Grade III RVU right
side Cryptorchidism
Prominent veins,
cutis laxa
IBD Steatorrhea Thick lips, prognathism
Pulmonary arterial
hypertension Polyarthritis
Yes
Death/sudden death
Yes WPW Sd Cryptorchidism Prominent veins,
cutis laxa
Steatorrhea Bilateral hearing loss Yes
Bilateral RVU Congenital right ptosis,
prominent lips, abnormal ear
Megaureter
B Yes stomatitis Pneunonitis No No Prominent veins m Kabuki syndrome like Yes
Portal cavernoma
Cerebral palsy
C Yes Mild dilatation of
ascendant aorta
No Prominent veins No Myopathy Polyarthritis No
Raynaud Hyperopia
Gastroesophageal reflux urinary
incontinence, Loose stools
D Yes Aortic insufficiency Cryptorchidism
micropenis
Prominent veins Failure to thrive Narrowed thorax No
Steatorrhea Inguinal hernia
IBD
E Yes ASD Aortic insufficiency Cryptorchidism Prominent veins No Frontal bossing, board nasal
bridge, jug ear Right strabism
Umbilical hernia
No
Tricuspid
regurgitation/surgery
Bilateral RVU Bilateral deafness
No Yes but no with
antibiotic prophylaxis
ASD Primary
pulmonary hypertension
No No No Board nasal bridge No
F Yes Pneumonitis cellulitis ASD/surgery Cryptorchidism Prominent veins IBD HTAP, dwarfism, Deafness No
Bilateral RVU
G Yes ASD/surgery A normal pregnancy
with normal child
Prominent veins No Very high voice No
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Table 1 Summary of the clinical and biological features of the 14 patients
Yes ASD/surgery planned Cryptorchidism Prominent veins No Precocious pubic hair growth
and delayed puberty
No
Death/sudden death
after sport activity
no autopsy
micropenis
H Yes sepsis No No Prominent veins Failure to thrive Enteral
nutriti on gastrostomy
Pierre robin sequence Major intellectual disability
with bilateral sus-tentorial
atrophy on MRILethal pyocyanic sepsis Brachiocephalic thrombosis
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http://www.ojrd.com/content/9/1/183cases, the disease remained unclassified for years. The
median term at birth was 37.5 weeks (interquartile
range (IQR): 36 ? 40 weeks), and five babies (35%) were
premature, being born between 30 and 35 weeks of
gestational age. The median birth weight was 2390 g (IQR:
2155? 2620), median length was 46 cm (IQR: 44? 48), and
median head circumference was 32 cm (IQR: 31.5? 35).
Six (42%) babies were considered to have had intrauterine
growth retardation.
Hematologic and immunological features
At the time of diagnosis, the median white blood cell count
(WBC) was 5.3 ? 10 9/l (IQR 2.5 ? 7.2 ? 10 9/l), absolute
neutrophil count (ANC) was 0.59 ? 10 9/l (IQR: 0.2 ?
1.97 ? 10 9/l), absolute lymphocyte count (ALC) was
2.7 ? 10 9/l (IQR: 1.7? 4.3 ? 10 9/l), and absolute monocyte
count (AMC) was 0.7 ? 10 9/L (IQR 0.37? 2.05 ? 10 9/l). On
the first available CBC, ANC was below 0.05 ? 10 9/l in
seven patients, between 0.5 and 1 ? 10 9/l in three patients,
and four patients had a count above 1.5 ? 10 9/l. The
median hemoglobin (Hb) level was 13.8 g/dl (IQR:
11.7 ? 18.9 g/dl), and platelet count was 177 ? 10 9/l
(IQR: 173 ? 297 ? 10 9/l). During routine follow-up, the
ANC fluctuated with time, without any detectable regular
variation. Taking into account all the available CBCs
recorded during the routine follow-up of the patients
(with the exception of the G-CSF therapy period), with a
median number of 23 per patient, the median WBC was
4 ? 10 9/l (IQR: 2.7? 4.5 ? 10 9/l), ANC was 0.53 ? 10 9/l
(IQR: 0.4 ? 0.7 ? 10 9/l), ALC was 1.7 ? 10 9/l (IQR: 1.6 ?
2.4 ? 10 9/l), and AMC was 0.55 ? 10 9/l (IQR: 0.34 ?
0.9 ? 10 9/l). The median Hb level was 12 g/dl (IQR:
10.9 ? 13 g/dl), and the median platelet count was 280 ?
109/l (IQR: 239 ? 353 ? 10 9/l). All patients had presented
at least one CBC with a neutropenia below 0.5 ? 10 9/l
during the follow-up.
Bone marrow smears, evaluated in 13 patients, were
centrally reviewed (HL) and globally failed to demon-
strate a bone marrow blockage (Figure 2). In almost all
cases, bone marrow was rich. The median percentage of
myeloid lineage was 66%, which was quite high compared
to the normal range (44 ? 50%) and could correspond to
a prolonged retention of neutrophils in the bone mar-
row. We observed a particular aspect of maturation
impairment compared to the usual aspect in congenital
neutropenia. Despite a normal percentage of mature
neutrophils, there was a relatively low rate of meta-
myelocytes during the myeloid differentiation. In most
cases (8/10), the morphologic aspect of myeloid neu-
trophils was unusual too, with nuclear hypolobulation
or a hypersegmentation with thin opening between
lobes, while the chromatin appeared condensed in sep-
arated clumps. There was no significant vacuolization
of myeloid cells. This particular cell morphology canbe considered to reflect myelokathexis. Megakaryocytic
differentiation showed dysplastic manifestations with
10% being micromegakaryocytes. The erythroid lineage
was normal in most cases, except for a macrocytosis
tendency. Therefore, the most characteristic morpho-
logical features were presence of micromegakaryocytes
and of neutrophils with hyperdense chromatin clumps,
and a usually normal percentage of myeloid cells with
an apparent lack of metamyelocytes (Figure 3).
Two patients developed severe transient anemia below
7 g/dl, and nine presented with mild transient anemia
between 7 and 10 g/dl. Thrombocytopenia was commonly
observed in our series, as nine developed at least one
episode of thrombocytopenia (severe <50 ? 10 9/l in three,
mild between 50 and 150 ? 10 9/l in six).
Plasma IgG was high in all patients (>3 SD) with a
median level (age >5 years) of 15.75 g/l (IQR: 13? 18) while
median IgA was 0.7 g/l and median IgM was 1.07 g/l, in
the normal range. Because of chronic bronchiectasis in
one patient lasting for 6 years, intravenous Ig was pro-
vided despite a high IgG level, without any effect on
the lung destruction; ultimately, the lung disease was
the cause of death. Crohn ? s disease (n = 3) and chronic
arthritis (n = 1) were observed, but no other autoimmune
manifestations were identified, and when assessed in three
cases, no autoantibodies were detected.
The lymphocyte phenotypes were roughly normal in
distribution. Counts were normal in six but low in four
evaluable patients (Table 2). However, the distribution of
naive T cells was diminished for the two patients in
whom this was tested. This low proportion of naive T
cells was present even in the absence of Crohn ? s disease
and regardless of age and immunosuppressive therapy.
Infection
Of 14 patients, 11 presented with at least one episode of
severe bacterial infection. A total of 64 episodes were
registered for the 11 patients. We observed no severe
viral infection. Various types of severe bacterial infections
were observed: cellulitis (n = 22), pneumonitis (n = 22), os-
teitis (n = 2), mastoiditis (n = 3), pyelonephritis (n = 10),
colitis with peritonitis (n = 1), and septicemia (n = 4). The
median age at the first severe infection was 13.1 years with
a large range from birth to age 29.7 years. Microbes were
documented in 31 episodes, and the most common were
Gram-negative bacteria in 17 episodes (E. coli, n = 7;
P. aeruginosa, n = 5; K. pneumoniae, n = 3; and other
Gram-negative species = 2) and Gram-positive cocci in
12 episodes (S. aureus, n = 6; pneumonia, n = 2; others,
n = 4); no Aspergillus spp. were identified, and candidiasis
was identified in two episodes.
In addition, all patients experienced multiple mild
infections early in childhood, mainly otitis, pharyngitis,
bronchitis, and gastroenteritis. Stomatitis was reported
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Figure 2 Bone marrow mean value of the differential count with standard deviation (n = 13).
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Figure 3 Bone marrow morphology in patients with G6PC3 congenital neutropenia. (A) Typical global bone marrow morphology: rich
cellularity with predominant granulopoiesis (G), some erythroblasts (E), and one micromegakaryocyte (MK). (B) Predominant granulopoiesis with
some myelocytes (M), very few metamyelocytes (MN), and a high number of mature neutrophils (N). (C) Details of neutrophils: hypersegmented
appearance with thin opening between lobes and chromatin clumps. (D) Examples of micromegakaryocytes.
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Table 2 Immunophenotype of 4 patients with G6PC3 severe chronic neutropenia
UPN
Age
527 3
age 50
Range of normal
values for an adult*
5805
age 3
Range of normal
values at age 3*
6536
age 1
Range of normal
values at age 1*
6262
age 6
Range of normal
values for at age 6*
IgG/A/M in g/dL 9.7 7.68-16.3 15.6 4.2-10.9 4.35. 3.32-11.6 18.7 6.08-12.29
1.7 0.68-3.78 0.55 0.22-1.57 0.32 0.14-1.05 1.7 0.33-2
1 0.60-2.63 0.7 0.45-2.63 0.34 0.45-1.90 1.7 0.46-1.97
Antibodies against
vaccine antigen
++ ++ ++
Lymphocytes 700 1400? 3300 831 2300? 5400 3100 3600? 8900 2800 2300? 5400
CD3+ 378 1200? 2000 698 1400? 3700 1891 2100? 6200 1960 2100? 6200
CD4+ 252 530? 1300 274.23 700? 2200 1178 1300? 3400 812 1300? 3400
CD8+ 98 330? 920 332.4 490? 1300 682 620? 2000 756 490? 1300
CD19+ 49 110? 570 58.17 390? 1400 651 720? 2600 364 390? 1400
CD16+ CD56+ 378 70? 480 698.04 130? 720 1891 180? 920 1960 130? 720
Distribution of naive/memory T cells
CD31+ CD45 +
CD4+ (N 43? 55%)
2 25
CD45+CD4+
(N 43? 55%)
19 37 27 50
CCR7 + CD45RA+/
CD8+ (N 52? 63%)
5 43
CCR7 +CD45RA-/
CD8+ (N 3? 14%)
7 6
CCR7 -CD45RA-/
CD8+ (N 20? 41%)
78 35
CCR7 -CD45RA+/
CD8+ (N 11? 26%)
10 16
*in gr/dl for immunoglobulins and in μL?10 -3 for lymphocytes.
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involving Pseudomonas aeruginosa. For two patients,
bronchiectasis complicated the pulmonary infection, and
these patients suffered from pulmonary insufficiency. One
of these patients died from acute respiratory failure at age
17 years.
G-CSF therapy and antibiotic prophylaxis
Antibiotic prophylaxis was common in the patients, based
on long-term use of cotrimoxazole (n = 9) or alternate
combined oral therapy (n = 2) but had a limited use for
preventing severe infections, neither bronchiectasis or
inflammatory bowel disease (IBD).
Nine patients were treated with G-CSF at a median
dose of 6.8 μg/kg and a cumulative dose of 867 μg/kg of
G-CSF per patient. In one patient, the response was poor
to G-CSF at a dose of 28 μg/kg/day while the response
was considered satisfactory in the other eight patients,
with a median neutrophil count varying from 0.533 X
109/l before G-CSF to 1.433 ? 10 9/l with G-CSF (P < 0.001).
G-CSF always was indicated for infection prevention. In
case of Crohn? s disease or IBDs, it appears to not have been
successful in limiting symptoms such as pain and chronic
diarrhea. Of note, oral steroids were prescribed to threepatients for arthritis and IBD, resulting in a constant
increase in neutrophils.
Leukemia
One case of leukemia was observed. Patient UPN5194 was
diagnosed at birth with aseptic meningitis. Neutropenia
was diagnosed as well as an aortic valvular insufficiency.
She later developed recurrent infections, including bron-
chitis, otitis, gastroenteritis, pharyngitis, osteitis, and urin-
ary infections. When she was one year old, a bilateral
vesico-ureteral reflux with bifid ureter was diagnosed.
Mild developmental delay was first noted in the first year
of life and improved later. When she was 13 years old,
blast cells were detected on blood examination performed
for pneumonitis. The bone marrow smear showed 13%
myeloblasts with dysgranulopoiesis. Acute myeloblastic
leukemia (AML) type M2 (FAB classification) was diag-
nosed 3 months later. The bone marrow karyotype
revealed a t(8;21)(q22;q22) translocation. Bone marrow
transplantation was performed when the patient was age
14 years using bone marrow from a healthy HLA-identical
sister and a conditioning regimen with cyclophospha-
mide and busulfan. A relapse of the AML was observed
12 months later, treated by two courses of an AML-like
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formed with the same donor and total body irradiation
and a cyclophosphamide regimen. No graft-versus-host
disease (GVHD) or relapse was observed, and the neu-
trophil count recovered after the transplant with full
engraftment. The long-term outcome showed a full donor
engraftment without GVHD, but chronic cardiomyopathy
was observed while the skin appearance and dysmorphia
remained. The patient was not able to become pregnant,
and this hypofertility could have been related to the condi-
tioning regimen.
Comorbidities
All patients in our survey had one or several comorbidi-
ties, as shown in Table 1.
Cardiac abnormalities
Cardiac abnormalities were observed in 12 of our patients:
an atrial septal defect in seven patients, another abnormal-
ity in four (aortic insufficiency in three and mild dilatation
of the ascending aorta in one), and a congenital rhythm
abnormality (Wolff-Parkinson-White) in one. Pulmonary
hypertension was present in three patients. The heart
defect was always severe, requiring surgery in five cases.
In addition to these presentations, two patients died sud-
denly in the third decade. In these cases, no autopsy was
performed, and no formal causes of death can be defined;
however, the circumstances of the deaths were the same.
After physical activity during the day, death occurred
during sleep (at age 30 years for both), which suggests a
paroxysmal heart rhythm abnormality.
Myopathy
A myopathic syndrome was observed in one female
(UPN5248/pedigree C). She was born at 39 weeks of
gestational age, weighing 2380 g (<3 SD) and at 44 cm
in length. Neutropenia was observed from age 7 days
(ANC 0.3 ? 10 9/l). Her medical history was that of
chronic severe neutropenia, with venous skin visibly
obvious from age 3 years. Despite normal psychomotor
development, sitting was acquired at 15 months and
walking at age 20 months. At age 2.5 years, she developed
recurrent episodes of muscle pains and cramps localized
to the proximal muscles, particularly the quadriceps. Such
cramps were intermittently observed with a number of
episodes from one per week to one per month and were
still present at the last update when she was age 20 years.
Initially, the cramps were considered to be related to G-
CSF therapy but appeared later to be independent of it.
Muscle strength was normal, but such episodes could
be aggravated by sport activity or even with limited
muscle effort. Because the etiology was not determined
from age 14 years, the association of the muscle cramps
and neutropenia has been extensively explored. Noneof the metabolic studies, including complete sequencing
of the mitochondrial DNA, showed abnormalities. Several
muscle biopsies were performed. Skeletal muscle sections
of biopsy showed mild variation in the fiber size (hema-
toxylin and eosin stain) and type 1 muscle fiber predomin-
ance (ATPase 9.40). With oxidative enzyme reactions for
nicotinamide adenine dinucleotide (NAD COX), the mesh
of the intermyofibrillar network appeared thickened
and slightly clumped, especially in type 2 fibers, which
exhibit mainly glycolytic metabolism. PAS staining showed
intense coloration in all muscle fibers, suggesting glycogen
accumulation (Figure 4).Urogenital abnormalities
Five patients required surgery because of severe vesico-
ureteral reflux. Six male patients had cryptorchidism.
Other urogenital anomalies were epispadias (n = 1),
hypospadias (n = 1), and megaureter (n = 1).Cutaneous abnormalities
Increased visibility of superficial veins is a known clinical
feature in G6PC3 deficiency, and 13 of our patients pre-
sented with this disorder. In pedigree E, consisting of two
patients, only one had a prominent superficial venous pat-
tern. Cutis laxa was noted in all patients of family A. In
two patients from this pedigree, skin biopsy, unfortunately
not available for a second review, showed a disappearance
of the hypodermis with collagen fiber hypertrophy.Nutrition and digestive tract
IBD or Crohn ? s disease was diagnosed on gut biopsy in
three patients. The first symptoms were recurrent abdom-
inal pains and chronic diarrhea. Age at first manifestation
of the digestive symptoms was young (between the ages of
6 and 10 years) even if gut biopsy to document IBD was
performed later between ages 10 and 15 years. No patients
in our survey were treated by anti-TNF alpha therapy, and
oral steroids appeared sufficient to improve symptomatol-
ogy. In two patients, bowel stenosis led to a partial colec-
tomy. Colon biopsy of patient UPN5131 showed acute
inflammatory infiltrate of the lamina propria with destruc-
tion of the epithelium, forming crypt abscesses with nu-
merous neutrophils, suggesting a local process attracting
the neutrophils, which became activated but could not
fulfill their roles (Figure 5). Each member of pedigree A
had an objective steatorrhea (>3 g/24 h); the cause of this
steatorrhea is not clear because no pancreatic insufficiency
was diagnosed, but pancreatic enzyme resulted in symp-
tom correction. One other patient also presented with
steatorrhea. One patient had a severe gastroesophageal
reflux. Of 14 patients, eight had growth failure with
weight < -3SD and height < -2SD.
A B
Figure 4 Pathological features of the muscle in patient UPN5248 with myopathic syndrome. (A) Serial skeletal muscle sections of biopsy
from patient 1 showed mild variation in fiber size (HE = hematoxylin and eosin stain) and type 1 muscle fiber predominance (ATPase 9.40). With
oxidative enzyme reactions (NADH, COX), the mesh of the intermyofibrillar network appeared thickened and slightly clumped, especially in type 2
fibers, which exhibit mainly glycolytic metabolism. (B) Skeletal muscle section of a biopsy from patient stained with PAS stain, showing intense
coloration in all muscle fibers.
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Seven patients had mental delay or learning difficulties.
One of them had an abnormal cerebral MRI with sus-
tentorial bilateral brain atrophy. This patient, who died
at age 5 years from septicemia, presented with severe
motor and psychomotor developmental delay. Delay in
psychomotor development in the first years of life with
age of walking between 18 and 24 months was observed
in half of the cases but did not preclude ultimately typ-
ical development.A B
Figure 5 Colon biopsy of patient UPN5131. (A) Low magnification of co
ulceration. (B) Higher magnification: acute inflammatory infiltrate of the lam
abscesses with numerous neutrophils. (C) High magnification showing cryp
destruction of some glands.Other pathologies
Six of fourteen patients had variable features of facial
dysmorphology, namely frontal bossing, thick lips, a
broad nasal bridge, and prognathism. One patient had
facial features present in Kabuki syndrome. One pa-
tient had a portal cavernoma, and one had Raynaud
syndrome. Two patients in our cohort had polyarthri-
tis treated with oral steroids, and two patients had
bilateral hearing loss. Puberty was delayed in one
patient.C
lic resection: mucosal lesion with acute inflammatory infiltrate and
ina propria with destruction of the epithelium, forming crypt
t abscesses: neutrophilic infiltration of the lamina propria with
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The 20-year survival and 30-year survival rates were 82%
and 44%, as shown on Figure 6 Eight patients reached age
18 years at minimum. As adults, two had a limited burden
of disease and were able to work, one after achieving a ter-
minal PhD and the other having no diploma. One of these
two patients was the mother of a healthy child. Six other
adults experienced severe limitations and were not able to
perform regular work. In one case (UPN5194), several
limitations such as cardiac and respiratory insufficiency,
hypogonadism, and hypothyroidism were attributable to
the hematopoietic stem cell transplantation performed
20 years earlier. As described, two patients died at around
age 30 years, suddenly and for unknown causes. The
circumstances of the deaths suggested that acute cardiac
dysrhythmia might have been responsible.
Discussion
We report a national survey of 14 cases of congenital
neutropenia related to G6PC3 mutations. A total of 61
cases have been reported [2,14-28] since the initial
description of the gene [2]. Because one of our cases has
already been described [2], here we have added 13 ori-
ginal cases to the literature.
Our national survey allowed us to estimate the inci-
dence rate at birth, which is estimated at 0.4/106 births
in the French population (95% confidence interval,
0.009 ? 0.9/106). The initial description [2] was based on
a population of Aramean ancestry, but we failed to con-
firm this as a common feature, and this disease appears
to be ubiquitous. Its terminology seems to be somewhat
controversial because several names have been proposed,
including SCN type 4 (MIM 610738) [19] or Dursun0
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Figure 6 Kaplan? Meier survival curve with 95% confidence interval (Csyndrome (MIM 613034 or 612541) [26], in addition to
G6PC3 neutropenia. The assignment of the number 4
for SCN seems rather inconsistent with the order of dis-
covery of the gene in congenital neutropenia. Dursun
syndrome is not really appropriate because we report
two publications of cases, one from 1982 [9] and one
from 1994 [8], the latter documented to be in relation to
the G6PC3 mutation. The term ?congenital neutropenia
associated with G6PC3 mutation ? appears to be the least
controversial and the most accurate.
Our report adds not only a significant number of cases
but also several important morbid associations. We
describe 14 patients from 8 families, in which six patients
are consanguineous. This neutropenia presents a large
extended phenotype. Among the 74 published cases,
including ours, only four (5%) were diagnosed without
any comorbidities [20]. The most frequent comorbidities
are prominent skin veins, urogenital malformations, and
heart malformations [2,22]. Our survey clarifies and ex-
tends the phenotype. With regard to cardiac abnormalities,
atrio-septal defect and patent ductus arteriosus are the
most frequently associated while primary pulmonary hyper-
tension has been described in 5/57 patients. Two patients
in our cohort also had pulmonary hypertension while two
had aortic regurgitation. Valvular anomalies have been also
described, but it is important to consider potentially lethal
paroxysmal heart rhythm trouble as a complication of
G6PC3 mutations. Such complications can be preceded
by early detection of Wolff-Parkinson-White abnormal-
ities but also may have a sole acute expression in young
adults, leading to sudden death.
Myopathic syndrome was mentioned briefly in the ini-
tial case publication (case #9) [2], and we provide here30 40 50
 in years
Survivor function
I) for the 14 patients with G6PC3 mutations in France.
Desplantes et al. Orphanet Journal of Rare Diseases 2014, 9:183 Page 13 of 15
http://www.ojrd.com/content/9/1/183more detailed clinical pathological findings of this case.
This myopathic syndrome is not attributable to a perman-
ent myopathic defect but is rather a critical event involving
recurrent cramps with effort. This manifestation was not
mentioned in the literature and appeared, on a pathological
basis, to be related to glycolytic metabolism impairment. In
the overall series, neurological development appeared to be
mildly delayed in the majority of cases. In one case among
14, the delay was significant and was associated with cere-
bral atrophy on MRI while in the other cases, it seemed
limited and transient, and one patient was able to pursue
studies up to the university level.
Our survey demonstrated that G6PC3 neutropenia may
also be associated with myelodysplasia and AML. Our
patient presented a myelodysplasia at age 14 years, fol-
lowed by AML 2 with translocation (8;21) six months
later. Such complications are already well known in the
great majority of congenital neutropenias [10,29], includ-
ing glycogen storage type Ib [30,31], but have not been
described so far in the 61 cases presented in the literature.
The case described here is the first case of a malignancy in
this type of neutropenia. This leukemia occurred in the
absence of G-CSF exposure and suggests that the risk of
leukemia, as in other congenital neutropenias, is associ-
ated with and results from the genetic defect itself. Of
note, hematopoietic stem cell transplant was a curative
option for this patient, who has survived 20 years past this
event and is still alive. Today, most patients with G6PC3
deficiency receive G-CSF, and a high dose of G-CSF is
correlated with an increased risk of leukemia; thus, these
data suggest the need to closely monitor the possibility of
leukemia in this patient group.
The occurrence of IBD in this population appears high.
With three cases out of 14 here and five cases docu-
mented in the literature [6,22,26], IBD is an important
comorbidity of G6PC3 neutropenia. The initial symptoms
in this series were recurrent abdominal pains. Such an
association is close to that described in glycogen storage
disease type Ib [32]. IBD appeared quite serious, and two
of our three patients had a bowel stenosis requiring partial
colectomy. IBD was also associated with chronic polyar-
thritis in one patient. This polyarthritis involved the large
joints but also the small joints and was not destructive. In
addition to IBD, arthritis can be controlled by oral low
dose steroid, which needs to be prolonged. Such an in-
flammatory process was not associated with autoimmune
markers or an associated infection and suggests more an
auto inflammatory process.
Our survey offers greater insight into the description
of the hematological features of G6CP3 neutropenia. In
the initial description by Botzug et al. [2], early myeloid
blockage was observed, but normal myeloid maturation
and myelokathexis features have been documented in
two cases with G6PC3 neutropenia [28]. When sequentialbone marrow aspiration is done, a bone marrow blockage
can occasionally be seen. However, our results, based on a
centralized review of all available bone marrow smears in
our survey, demonstrated that the most regular aspect of
bone marrow is the absence of maturation arrest in this
genetic disorder.
As described in one case report, we confirm that in
addition to lymphopenia, G6CP3 neutropenia involves a
relative deficiency of naive T cells. These immunological
features are not associated with IBD or chronic viral infec-
tions and seem likely to be secondary to chronic infections
related to the neutropenia.
Thus far among the 61 described cases, four deaths
have been reported, one at birth [3], one at 9 months
from sepsis [14], and two at 18 months [17]. In the
current series, with the largest follow-up reported so far,
we observed a higher death rate, mainly in young adults.
One death from sepsis occurred at age 5 years, but the
three other deaths occurred in young adults, one at age
19 years from the final stage of pulmonary insufficiency
and two at around age 30 years, both sudden deaths sug-
gesting acute cardiac dysrythmia.
Our study was not oriented to the pathophysiology of
the G6PC3 defect; however, the very large number of
clinical manifestations related to this defect highlights the
ubiquitous role of the glucose-6-phosphatase subprotein
3. This protein belongs to the glucose-6-phosphatase
complex, which has the major role of releasing glucose
from glucose-6-phosphate, a key step in neoglucogenesis.
This pathway, however, is not really altered in the human
G6PC3 defect, and patients had no impairment in glucose
homeostasis. Rather, mutations in this protein affect
embryogenesis of the heart, urogenital tract, and central
nervous system. In addition, this defect results in a very
specific neutropenia characterized by a neutrophil release
defect rather than by a maturation arrest and appears to
be a consequence of the endoplasmic reticulum stress
pathway as well as the glycosylation of proteins. Rigorous
mass spectrometric glycomic profiling has shown that
most of the complex-type antennae that characterize the
neutrophil N-glycome of healthy individuals are severely
truncated in patient neutrophils. A comparable truncation
of the core 2 antenna of the O-glycans has also been ob-
served. This aberrant neutrophil glycosylation is predicted
to have profound effects on neutrophil function and merit
designation of this syndrome both syndromes as a new
class of congenital disorders of glycosylation [33].Abbreviations
ALC: Absolute lymphocyte count; AMC: Absolute monocyte count;
ANC: Absolute neutrophil count; GCSF: Granulocyte colony-stimulating factor;
G6PC3: Glucose-6-phosphatase, catalytic subunit 3 gene; Hb: Hemoglobin;
IUGR: Intrauterine growth retardation; IQR: Interquartile range; SD: Standard
deviation; SF: Shortening fraction; UPN: Unique patient number; WBC: White
blood cell count; IBD: Inflammatory bowel disease.
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